Logo image of BSX

BOSTON SCIENTIFIC CORP (BSX) Stock Fundamental Analysis

USA - NYSE:BSX - US1011371077 - Common Stock

104.22 USD
+4.32 (+4.32%)
Last: 10/22/2025, 2:53:08 PM
Fundamental Rating

5

Overall BSX gets a fundamental rating of 5 out of 10. We evaluated BSX against 190 industry peers in the Health Care Equipment & Supplies industry. While BSX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. BSX is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

In the past year BSX was profitable.
In the past year BSX had a positive cash flow from operations.
Of the past 5 years BSX 4 years were profitable.
Each year in the past 5 years BSX had a positive operating cash flow.
BSX Yearly Net Income VS EBIT VS OCF VS FCFBSX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

1.2 Ratios

BSX has a better Return On Assets (6.03%) than 83.68% of its industry peers.
The Return On Equity of BSX (11.17%) is better than 87.37% of its industry peers.
BSX's Return On Invested Capital of 7.66% is amongst the best of the industry. BSX outperforms 84.21% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BSX is below the industry average of 8.88%.
The 3 year average ROIC (6.54%) for BSX is below the current ROIC(7.66%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.03%
ROE 11.17%
ROIC 7.66%
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
BSX Yearly ROA, ROE, ROICBSX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

Looking at the Profit Margin, with a value of 13.54%, BSX belongs to the top of the industry, outperforming 91.05% of the companies in the same industry.
In the last couple of years the Profit Margin of BSX has declined.
Looking at the Operating Margin, with a value of 18.69%, BSX belongs to the top of the industry, outperforming 90.00% of the companies in the same industry.
BSX's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 68.30%, BSX is in the better half of the industry, outperforming 75.26% of the companies in the same industry.
BSX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 18.69%
PM (TTM) 13.54%
GM 68.3%
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
BSX Yearly Profit, Operating, Gross MarginsBSX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BSX is destroying value.
BSX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BSX has been increased compared to 5 years ago.
The debt/assets ratio for BSX is higher compared to a year ago.
BSX Yearly Shares OutstandingBSX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B
BSX Yearly Total Debt VS Total AssetsBSX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

An Altman-Z score of 5.55 indicates that BSX is not in any danger for bankruptcy at the moment.
BSX's Altman-Z score of 5.55 is fine compared to the rest of the industry. BSX outperforms 80.00% of its industry peers.
The Debt to FCF ratio of BSX is 3.33, which is a good value as it means it would take BSX, 3.33 years of fcf income to pay off all of its debts.
BSX has a Debt to FCF ratio of 3.33. This is amongst the best in the industry. BSX outperforms 85.79% of its industry peers.
BSX has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
BSX has a Debt to Equity ratio (0.50) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF 3.33
Altman-Z 5.55
ROIC/WACC0.93
WACC8.22%
BSX Yearly LT Debt VS Equity VS FCFBSX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B 20B

2.3 Liquidity

A Current Ratio of 1.37 indicates that BSX should not have too much problems paying its short term obligations.
With a Current ratio value of 1.37, BSX is not doing good in the industry: 77.89% of the companies in the same industry are doing better.
BSX has a Quick Ratio of 1.37. This is a bad value and indicates that BSX is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of BSX (0.82) is worse than 83.68% of its industry peers.
Industry RankSector Rank
Current Ratio 1.37
Quick Ratio 0.82
BSX Yearly Current Assets VS Current LiabilitesBSX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

8

3. Growth

3.1 Past

BSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.91%, which is quite impressive.
BSX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 9.56% yearly.
The Revenue has grown by 21.45% in the past year. This is a very strong growth!
The Revenue has been growing by 9.30% on average over the past years. This is quite good.
EPS 1Y (TTM)26.91%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%20.97%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%22.84%

3.2 Future

BSX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.40% yearly.
BSX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.12% yearly.
EPS Next Y19.98%
EPS Next 2Y16.93%
EPS Next 3Y15.51%
EPS Next 5Y14.4%
Revenue Next Year19.71%
Revenue Next 2Y15.31%
Revenue Next 3Y13.67%
Revenue Next 5Y12.12%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BSX Yearly Revenue VS EstimatesBSX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10B 20B 30B
BSX Yearly EPS VS EstimatesBSX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1 2 3 4 5

4

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 36.83 indicates a quite expensive valuation of BSX.
BSX's Price/Earnings ratio is a bit cheaper when compared to the industry. BSX is cheaper than 71.05% of the companies in the same industry.
BSX's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 27.77.
BSX is valuated quite expensively with a Price/Forward Earnings ratio of 30.37.
BSX's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BSX is cheaper than 73.16% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.23. BSX is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 36.83
Fwd PE 30.37
BSX Price Earnings VS Forward Price EarningsBSX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BSX indicates a somewhat cheap valuation: BSX is cheaper than 70.53% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BSX indicates a somewhat cheap valuation: BSX is cheaper than 77.37% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 44.32
EV/EBITDA 33.34
BSX Per share dataBSX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BSX does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of BSX may justify a higher PE ratio.
A more expensive valuation may be justified as BSX's earnings are expected to grow with 15.51% in the coming years.
PEG (NY)1.84
PEG (5Y)3.85
EPS Next 2Y16.93%
EPS Next 3Y15.51%

0

5. Dividend

5.1 Amount

BSX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BOSTON SCIENTIFIC CORP

NYSE:BSX (10/22/2025, 2:53:08 PM)

104.22

+4.32 (+4.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-23 2025-07-23/bmo
Earnings (Next)10-22 2025-10-22/bmo
Inst Owners93.27%
Inst Owner Change-0.25%
Ins Owners0.15%
Ins Owner Change-1.6%
Market Cap154.43B
Revenue(TTM)18.49B
Net Income(TTM)2.50B
Analysts86.34
Price Target126.25 (21.14%)
Short Float %1.29%
Short Ratio2.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.53%
Min EPS beat(2)2.49%
Max EPS beat(2)10.56%
EPS beat(4)4
Avg EPS beat(4)6.23%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.12%
EPS beat(12)11
Avg EPS beat(12)5.14%
EPS beat(16)15
Avg EPS beat(16)4.28%
Revenue beat(2)2
Avg Revenue beat(2)1.7%
Min Revenue beat(2)0.97%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)2.15%
Min Revenue beat(4)0.97%
Max Revenue beat(4)3.16%
Revenue beat(8)8
Avg Revenue beat(8)2.1%
Revenue beat(12)11
Avg Revenue beat(12)2.01%
Revenue beat(16)12
Avg Revenue beat(16)1.41%
PT rev (1m)0%
PT rev (3m)4.27%
EPS NQ rev (1m)0.05%
EPS NQ rev (3m)2.33%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)2.17%
Revenue NQ rev (1m)0.22%
Revenue NQ rev (3m)2.28%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)2.02%
Valuation
Industry RankSector Rank
PE 36.83
Fwd PE 30.37
P/S 8.35
P/FCF 44.32
P/OCF 36.05
P/B 6.89
P/tB N/A
EV/EBITDA 33.34
EPS(TTM)2.83
EY2.72%
EPS(NY)3.43
Fwd EY3.29%
FCF(TTM)2.35
FCFY2.26%
OCF(TTM)2.89
OCFY2.77%
SpS12.48
BVpS15.13
TBVpS-1.97
PEG (NY)1.84
PEG (5Y)3.85
Graham Number31.04
Profitability
Industry RankSector Rank
ROA 6.03%
ROE 11.17%
ROCE 9.51%
ROIC 7.66%
ROICexc 7.77%
ROICexgc 26.52%
OM 18.69%
PM (TTM) 13.54%
GM 68.3%
FCFM 18.84%
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
ROICexc(3y)6.7%
ROICexc(5y)5.9%
ROICexgc(3y)22.68%
ROICexgc(5y)19.43%
ROCE(3y)8.12%
ROCE(5y)7.05%
ROICexgc growth 3Y8.56%
ROICexgc growth 5Y6.81%
ROICexc growth 3Y4.36%
ROICexc growth 5Y5.23%
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
F-Score5
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF 3.33
Debt/EBITDA 2.33
Cap/Depr 60.84%
Cap/Sales 4.33%
Interest Coverage 250
Cash Conversion 89.77%
Profit Quality 139.08%
Current Ratio 1.37
Quick Ratio 0.82
Altman-Z 5.55
F-Score5
WACC8.22%
ROIC/WACC0.93
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.91%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%20.97%
EPS Next Y19.98%
EPS Next 2Y16.93%
EPS Next 3Y15.51%
EPS Next 5Y14.4%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%22.84%
Revenue Next Year19.71%
Revenue Next 2Y15.31%
Revenue Next 3Y13.67%
Revenue Next 5Y12.12%
EBIT growth 1Y26.44%
EBIT growth 3Y12.47%
EBIT growth 5Y10.54%
EBIT Next Year35.51%
EBIT Next 3Y19.85%
EBIT Next 5Y17.06%
FCF growth 1Y131.03%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y101.7%
OCF growth 3Y22.44%
OCF growth 5Y13.34%